Tevogen Bio's TVGN-489 Valued Up to $11 Billion
Warren, Monday, 8 September 2025.
Tevogen Bio Holdings Inc. announced a risk-adjusted net present value of $9-11 billion for its first clinical product, TVGN-489, potentially attracting significant investor interest and strategic partnerships.
A Major Milestone for Tevogen Bio
On September 8, 2025, Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced a significant milestone in its corporate journey by revealing the risk-adjusted net present value (rNPV) of its first clinical product, TVGN-489, to be between $9 billion and $11 billion. This valuation underscores the potential of TVGN-489, which is an allogeneic precision T cell therapy developed to treat SARS-CoV-2 infections and Long-COVID in high-risk patients [1].
Clinical Developments and Implications
TVGN-489 has shown promising results in its Phase I Proof-of-Concept study, published in Blood Advances. The study involved high-risk ambulatory patients, 50% of whom were immunocompromised, receiving single infusions of TVGN-489 across four escalating dose levels. The therapy was well tolerated, exhibiting no dose-limiting toxicities or severe immune reactions. Notably, nasal PCR tests demonstrated significant viral elimination, with 92% of patients showing ≥88% elimination by Day 4, and 100% achieving >99% elimination by Day 14. These results suggest that TVGN-489 is effective in treating COVID-19 without impairing the patient’s immune responses [1][2].
Strategic and Financial Prospects
The valuation announcement is expected to attract significant investor interest and open doors for strategic partnerships. D. Boral Capital recently reaffirmed a ‘buy’ rating for Tevogen Bio stock, with a price target of $10.00, indicating strong market confidence in the company’s future prospects [3][4]. With TVGN-489 as a cornerstone, Tevogen Bio is poised to leverage its proprietary ExacTcell™ technology platform to address unmet clinical needs, particularly in infectious diseases and oncology [1][3].
Navigating Challenges and Looking Ahead
Despite these advancements, Tevogen Bio faces challenges typical of a clinical-stage company, including the need for additional capital to execute its business plans and the risks associated with regulatory hurdles and intellectual property protection. However, with its innovative approach and recent clinical successes, the company is well-positioned to navigate these challenges. As Tevogen Bio continues to develop its product pipeline, including therapies for multiple sclerosis and EBV-associated lymphomas, its strategic focus on high-impact areas is expected to yield substantial long-term benefits [1][2].